Topical erythromycin and zinc therapy for acne

Area of Science:

• Dermatology
• Pharmacology

Background:

• Acne vulgaris is a common skin condition with various treatment options.
• Topical antibiotics and zinc formulations are used to manage acne.
• Evaluating combination therapies is crucial for optimizing acne treatment.

Purpose of the Study:

• To assess the safety and efficacy of a 4% erythromycin plus 1.2% zinc acetate formulation for acne treatment.
• To compare the combination therapy against its vehicle over a 12-week period.
• To evaluate long-term safety and efficacy over a 40-week extension period.

Main Methods:

• A 12-week, double-blind, vehicle-controlled study involving female patients with acne.
• Patients were randomized to receive either the erythromycin-zinc formulation or its vehicle.
• A 40-week open-label extension phase followed, with treatment crossover for vehicle-treated patients.

Main Results:

• Statistically significant improvements in acne severity grades and counts of papules, pustules, and comedones were observed in the erythromycin-zinc group compared to the vehicle group within 12 weeks.
• Following crossover, patients initially treated with the vehicle showed comparable improvements when switched to the active treatment.
• No instances of superinfection or secondary infection were reported during the one-year study period.

Conclusions:

• The 4% erythromycin plus 1.2% zinc acetate formulation demonstrates significant efficacy in treating acne vulgaris.
• The treatment is well-tolerated, with no significant safety concerns related to infection over one year.
• Combination therapy offers a safe and effective option for managing acne severity.